Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Rani Therapeutics Holdings (RANI) Receivables - Net (2025 - 2026)

Rani Therapeutics Holdings' Receivables - Net history spans 2 years, with the latest figure at $2.0 million for Q1 2026.

  • On a quarterly basis, Receivables - Net rose 240.33% to $2.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $2.0 million, a 240.33% increase, with the full-year FY2025 number at $2.0 million, changed N/A from a year prior.
  • Receivables - Net came in at $2.0 million for Q1 2026, roughly flat from $2.0 million in the prior quarter.
  • The five-year high for Receivables - Net was $2.0 million in Q4 2025, with the low at $600000.0 in Q1 2025.